Werewolf Therapeutics

OverviewSuggest Edit

Werewolf Therapeutics is an oncology biotherapeutics company that develops cancer treatments designed to focus the body’s immune response to selectively target cancer. Its products are used for the treatment of advanced solid tumors, relapsed or refractory advanced or metastatic solid tumors, lymphoma, and hematologic malignancies.

TypePublic
Founded2017
HQCambridge, MA, US
Websitewerewolftx.com

Latest Updates

Employees (est.) (Mar 2021)28
Job Openings2
Share Price (Sept 2021)$17.8(+3%)
Cybersecurity ratingBMore

Key People/Management at Werewolf Therapeutics

Dan Hicklin

Dan Hicklin

President, Chief Executive Officer and Board Member
Cynthia Seidel-Dugan

Cynthia Seidel-Dugan

Chief Scientific Officer
Reid Leonard

Reid Leonard

Chief Operating Officer
Randi Isaacs

Randi Isaacs

Chief Medical Officer
William Winston

William Winston

Vice President, Research
Ellen Lubman

Ellen Lubman

Chief Business Officer
Show more

Werewolf Therapeutics Office Locations

Werewolf Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
1030 Massachusetts Ave #210
Show all (1)

Werewolf Therapeutics Financials and Metrics

Werewolf Therapeutics Revenue

Market capitalization (17-Sept-2021)

491.3m

Closing stock price (17-Sept-2021)

17.8
Werewolf Therapeutics's current market capitalization is $491.3 m.
Show all financial metrics

Werewolf Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Werewolf Therapeutics Online and Social Media Presence

Embed Graph

Werewolf Therapeutics News and Updates

Werewolf Therapeutics to Present at Upcoming Next-Gen Cytokine Therapeutics Summit

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced …

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program

Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, condit…

Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will be …

Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer

Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing

Werewolf Therapeutics Reports First Quarter 2021 Financial Results

- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -

Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced …
Show more

Werewolf Therapeutics Blogs

Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer

Veteran life sciences executive brings more than 30 years CMC and product development strategy expertise to rapidly advance programs and oversee manufacturing The post Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer appeared first on Werewolf Therapeutics.

Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors

Over 30 years of experience in advancing therapeutics to commercial launch and driving companies to successful operations and strategic transactions. The post Werewolf Therapeutics Appoints Mike Sherman to its Board of Directors appeared first on Werewolf Therapeutics.

Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company The post Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021 appeared first on Werewolf Therapeutics.

Werewolf Therapeutics Appoints Tim Trost as Chief Financial Officer

Veteran life sciences financial executive brings over 25 years finance and capital markets expertise Cambridge, Mass., February 8, 2021 – Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate th…

Werewolf Therapeutics Appoints Dr. Randi Isaacs as Chief Medical Officer

Expansion of leadership team with deep translational oncology drug development expertise as Company prepares for clinical development of lead programs Cambridge, Mass., November 9, 2020 – Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative canc…

Werewolf Therapeutics Frequently Asked Questions

  • When was Werewolf Therapeutics founded?

    Werewolf Therapeutics was founded in 2017.

  • Who are Werewolf Therapeutics key executives?

    Werewolf Therapeutics's key executives are Dan Hicklin, Cynthia Seidel-Dugan and Reid Leonard.

  • How many employees does Werewolf Therapeutics have?

    Werewolf Therapeutics has 28 employees.

  • Who are Werewolf Therapeutics competitors?

    Competitors of Werewolf Therapeutics include Jiangsu Hansoh Pharmaceutical Group, 3sbio and Kyowa Kirin.

  • Where is Werewolf Therapeutics headquarters?

    Werewolf Therapeutics headquarters is located at 1030 Massachusetts Ave #210, Cambridge.

  • Where are Werewolf Therapeutics offices?

    Werewolf Therapeutics has an office in Cambridge.

  • How many offices does Werewolf Therapeutics have?

    Werewolf Therapeutics has 1 office.